Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study.
Sandro Pignata(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrew R. Clamp, Constanta Timcheva, Radosław Mądry(Nordic Society of Gynecologic Oncology), Zahid Bashir(AstraZeneca (United Kingdom)), Geoff Hall(University of Leeds), Nicoletta Colombo(University of Milano-Bicocca), Rosalind Glasspool(Institut Bergonié), Imre Pete(National Institute of Oncology), Jaroslav Klát(University Hospital Ostrava), Amit M. Oza(Ontario Institute for Cancer Research), David Cibula(Charles University), Alan Barnicle(AstraZeneca (United Kingdom)), Beatriz Pardo(Duran i Reynals Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Ana Herrero(Hospital Universitario Miguel Servet), Rosemary Taylor(AstraZeneca (United Kingdom)), Massimo Di Maïo(University of Siena), Rumyana Ilieva, Margarita Romeo(Institut Català d'Oncologia)
Cited by 5
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k